Related Experiment Video

Updated: Mar 30, 2026

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

8.4K

Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma

Francesco Massari1, Chiara Ciccarese1, Matteo Santoni2

  • 1a Medical Oncology , Azienda Ospedaliera Universitaria Integrata, University of Verona , Verona , Italy.

Expert Review of Anticancer Therapy
|November 17, 2015
PubMed

Insights

Targeting the Fibroblast Growth Factor (FGF)/FGF Receptor (FGFR) pathway may overcome resistance to VEGF-targeted therapies by inhibiting tumor angiogenesis. This approach shows promise for renal cell carcinoma treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Tumor angiogenesis, crucial for cancer growth, can become independent of vascular endothelial growth factor (VEGF).
  • The Fibroblast Growth Factor (FGF)/FGF Receptor (FGFR) pathway acts as a compensatory mechanism in VEGF-independent angiogenesis.
  • This compensatory pathway contributes to resistance against VEGF-targeted therapies in various cancers.

Purpose of the Study:

  • To review the role of the FGF/FGFR pathway in renal cell carcinoma (RCC) pathogenesis.
  • To discuss the potential of targeting the FGF/FGFR axis to overcome resistance to VEGF-targeted therapies in RCC.
  • To highlight ongoing clinical trials investigating novel agents targeting the FGF/FGFR pathway in RCC.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of the molecular mechanisms underlying FGF/FGFR signaling in RCC.
  • Summary of ongoing clinical trials for FGF/FGFR inhibitors in RCC.

Main Results:

  • The FGF/FGFR pathway is implicated in driving VEGF-independent tumor angiogenesis in RCC.
  • Inhibition of the FGF/FGFR axis demonstrates potential in sensitizing tumors to VEGF-targeted therapies.
  • Emerging agents targeting FGF/FGFR are under investigation in various phases of clinical trials for RCC.

Conclusions:

  • Targeting the FGF/FGFR pathway represents a promising strategy to combat tumor angiogenesis and resistance in RCC.
  • Further research and clinical trials are warranted to establish the efficacy of FGF/FGFR-targeted agents in RCC treatment.
Keywords:
fibroblast growth factor receptorkidneypersonalized medicineprecision medicinerenal cell carcinomatargeted therapyvascular endothelial growth factor receptor

More Related Videos

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.3K
Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection10:15

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

2.3K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.9K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
4.0K